Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
July 30, 2014, 11:47:39 PM

Login with username, password and session length


Members
Stats
  • Total Posts: 632466
  • Total Topics: 47900
  • Online Today: 294
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: GeoVax opens third clinical trial site for testing HIV/AIDS vaccine  (Read 2478 times)

0 Members and 1 Guest are viewing this topic.

Offline John2038

  • Member
  • Posts: 1,529
  • Happiness is a journey, not a destination.
    • HIV Research News (Twitter)
GeoVax opens third clinical trial site for testing HIV/AIDS vaccine
The therapeutic trial is the first trial to test the GeoVax vaccine as a possible treatment for HIV-infected people.

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced today the opening of a third site for testing the therapeutic potential of its HIV/AIDS vaccine. The Los Angeles-based AIDS Research Alliance (ARA) will join with two existing members of GeoVax's clinical trial site team: the AIDS Research Consortium of Atlanta and the Alabama Vaccine Research Clinic at the University of Alabama at Birmingham. The ARA is the nation's only independent, nonprofit HIV/AIDS research institute.

The therapeutic trial is the first trial to test the GeoVax vaccine as a possible treatment for HIV-infected people. Studies with simian prototypes of the vaccine in infected non-human primates have demonstrated the ability to control viral replication in the absence of anti-viral drugs. The clinical trial in HIV-infected patients will test safety, vaccine-induced immune responses and the ability of the vaccine to control viral replication.

"We are excited to expand our therapeutic trial team to include the AIDS Research Alliance," said Mark Newman, PhD, Vice President of Research and Development at GeoVax. "They are a group with a mission that parallels that of GeoVax, developing a vaccine to prevent infection by HIV and developing better treatments for those who become infected."

Dr. Stephen Brown, ARA's medical director, said, "The ARA leadership is very familiar with the GeoVax HIV vaccine products through our involvement with the HVTN, and we are excited to participate in this clinical trial. The development of new products and approaches that build upon existing antiretroviral drugs regimens would be a major breakthrough."

To be eligible for the study, potential volunteers must have started antiretroviral therapy within 18 months of a negative HIV antibody test and must remain on stable antiretroviral therapy for six months prior to receiving their first dose of the vaccines. Multiple potential candidates, identified through the AIDS Research Consortium of Atlanta and the Alabama Vaccine Research Clinic, are currently in the six-month antiretroviral therapy period and the vaccination segment of the clinical trial will soon be initiated.

The GeoVax vaccines are currently being tested in HIV-uninfected persons in a Phase 2 clinical trial by the HIV Vaccine Trials Network (HVTN). The HVTN trials are funded by the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health. The therapeutic trial is the first GeoVax trial designed to test these vaccines as a treatment for HIV-infected persons.

GeoVax Labs, Inc.


http://www.geovax.com/

Offline jeezx

  • Member
  • Posts: 21
Re: GeoVax opens third clinical trial site for testing HIV/AIDS vaccine
« Reply #1 on: June 25, 2011, 11:49:17 AM »
the main purpose of this vaccine is to keep people off HAART?

How long will it take starting from this phase if they ever make it?

Offline tash08

  • Member
  • Posts: 86
Re: GeoVax opens third clinical trial site for testing HIV/AIDS vaccine
« Reply #2 on: July 02, 2011, 08:28:10 PM »
GeoVax's Phase 1 study estimated completion date is December 2013. If everything goes well it should take 8-10 years to be completed, but only time will show how effective it will be.

GV-TH-01 is an open label Phase 1 study of 10 HIV-1 infected adults with suppressed viremia who started ART within 18 months of a negative HIV antibody test. This study has 3 phases. The first phase is the vaccination phase, where patients are vaccinated with pGA2/JS7 DNA and MVA62B vaccines on a prime/boost regimen at weeks 1 and 9 (JS7 DNA vaccine) and weeks 17 and 25 (MVA62B). Both vaccines encode Gag, Pol, and Env. The second phase of the study is a treatment interruption phase, whereby ART is interrupted for a 12 week period approximately 8 weeks following the last vaccination. The third phase occurs after the 12 week treatment interruption phase and is called the treatment reinstitution phase, because subjects reinstitute ART and are followed for an additional 24 weeks. The primary objective is to evaluate the safety of the vaccines during the three treatment phases. A secondary objective is to evaluate the immunogenicity of the vaccines during the vaccination phase of the study.

http://clinicaltrials.gov/ct2/show/NCT01378156?term=geovax&rank=1

« Last Edit: July 02, 2011, 08:30:30 PM by tash08 »
01/04/06-HIV-
03/09/06-HIV+
05/07-Atripla
04/01/10 CD4-681, VL-UD
07/10/10 CD4-450, VL-UD
10/10/10 CD4-473, VL-UD
01/21/11 cd4-522, VL-UD
05/02/11 CD4-638, VL-UD <20 copies Hell yeah!
08/3/12 CD4-806, VL-UD

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.